Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Top Ten Searches
post partum incontinence fibroid hpv colpotomy ovarian cyst curettage endometriosis intrauterine umbilical cordYour Article Summary
See Latest ArticlesImmunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas)
Modern Pathology, 09/24/07
Lerma, E., et al. - Basal breast carcinomas triple negative for estrogen receptors, progesterone receptors and Her2/neu breast carcinomas are more aggressive than conventional neoplasms. We studied 64 cases with immunohistochemistry, using 23 antibodies, to characterize diverse pathological pathways. A basal cytokeratin was identified in 81% of tumors and vimentin was identified in 55%. The mean Ki67 index was 46% (range, 10–90%)
| Previous Article | Next Article |
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of intraductal papillomas of the breast
Annals of Surgical Oncology, 06/03/09
Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial
The American Journal of Surgery, 06/25/09
Nipple-Sparing Mastectomy
Plastic and Reconstructive Surgery, 06/19/09
Sponsor
Article Search
Sponsor